Laura Kanouse Vining

Associate

亚特兰大 + 1.404.581.8352

联系：

Share

Laura Kanouse Vining focuses her practice on biotechnology and pharmaceutical intellectual property litigation, including complex Hatch-Waxman litigation. Her experience includes representing clients in various U.S. district courts and before the International Trade Commission (ITC) and Patent Trial and Appeal Board (PTAB).

Laura leverages her technical background to defend and enforce clients' intellectual property rights in cutting-edge technology, including CRISPR (clustered regularly interspaced short palindromic repeats), proteomics, small molecule drugs, bioelectronics, and medical devices. Her litigation experience includes all phases of pretrial litigation. She has drafted motions, assisted with hearings, managed discovery, and deposed several fact witnesses. Laura also has worked extensively with expert witnesses, including assisting in drafting expert reports and preparing expert witnesses for depositions.

Laura is also deeply committed to pro bono work and community involvement. Recently, she was lead associate on a trial team that won grant of asylum for a family of four as part of the Firm's Border Project. In addition, she serves on the Advisory Board for Georgia Lawyers for the Arts, a nonprofit organization that provides legal assistance and educational programming to artists and inventors.

经验

  • Axion resolves 3-patent, false advertising, and trade secret DDE case after jury selectionJones Day defended Axion BioSystems, Inc. ("Axion") against Agilent Technologies, Inc. ("Agilent") which asserted patent infringement, false advertising, trade secret misappropriation, and intentional and negligent interference with prospective economic advantage claims in the U.S. District Court for the District of Delaware.
  • Axion resolves patent infringement suit in DDE regarding its impedance-based, live-cell analysis productsJones Day defended Axion BioSystems, Inc. ("Axion") against a patent infringement lawsuit filed in the U. S. District Court for the District of Delaware by Agilent Technologies, Inc. ("Agilent").
  • Merck's BRIDION® Hatch-Waxman trial victory on patent term extension issue affirmed at CAFCJones Day represented Merck Sharp & Dohme, B.V. in Hatch-Waxman patent infringement actions originally filed against 16 generic drug maker defendant groups, relating to the defendant groups' Abbreviated New Drug Applications (ANDA) seeking approval of generic versions of BRIDION®, a first-in-class agent for the reversal of certain types of neuromuscular blockade in adults undergoing surgery.
  • Ultragenyx files ANDA patent suit against three generic-drug manufacturers involving DOJOLVI®Jones Day represents plaintiff Ultragenyx Pharmaceutical Inc. in asserting claims of patent infringement under the Hatch-Waxman Act involving a life-saving pharmaceutical product known as Dojolvi® (triheptanoin) against three generic manufacturers seeking to market generic versions of triheptanoin oral liquid.
  • Venezuelan family obtains asylum for protection of political opinionJones Day obtained a grant of asylum for a Venezuelan family of three.
  • SHEnB resolves patent infringement claims brought at the ITC involving skin treatment devicesJones Day was lead counsel defending Sung Hwan E&B Co., Ltd. ("SHEnB"), a Korean manufacturer of medical devices for the health & beauty industry, and two of its distributors against patent infringement claims brought by Serendia, LLC before the International Trade Commission.
  • Ricoh resolves Lanham Act case involving its global "imagine. change." tagline in D. Minn.Jones Day defended Ricoh Co., Ltd. and Ricoh USA, Inc. in a Lanham Act case in the District of Minnesota in which a commercial printing company accused Ricoh of infringing certain trademarks owned by the plaintiff.
  • Specialty engineered woods manufacturer reaches settlement in trade secret and supply agreement disputeJones Day represented an industry leader in the manufacture of specialty engineered wood products in a lawsuit against a supplier involving allegations of misappropriation of trade secrets, breach of contract, tortious interference, and unfair competition.
  • ToolGen faces off in two patent interferences involving CRISPR/Cas9 applicationJones Day is representing ToolGen, Inc. in two patent interferences involving CRISPR/Cas9 technology.
    •

    February 2022 Commentary

    Tillis Urges FDA, USPTO to Investigate Potential False Narrative by Drug Critics

    December 2021 White Paper

    Navigating Trade Secret Identification During Discovery: Timing & Scope

    发送前请注意

    *Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice